Reaction
Colon Operation reporting signals
As of the last recalculation, Colon Operation appears in 1,170 FAERS reports alongside 11 co-occurring drug terms. The strongest observed disproportionality signal is RISANKIZUMAB-RZAA (PRR 21.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Risankizumab-Rzaa | 91 | 21.4 | 21.4 |
| Panitumumab | 13 | 14.9 | 14.9 |
| Upadacitinib | 49 | 11.1 | 11.1 |
| Vedolizumab | 38 | 8.1 | 8.1 |
| Imatinib Mesylate | 12 | 7.7 | 7.7 |
| Bosentan | 20 | 7.2 | 7.2 |
| Rucaparib | 3 | 6.1 | 6.1 |
| Ranolazine | 3 | 5.1 | 5.1 |
| Bimekizumab | 5 | 4.2 | 4.2 |
| Relugolix | 4 | 3.0 | 3.0 |
| Pimavanserin Tartrate | 5 | 1.6 | 1.6 |